EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain

Thursday, October 10, 2019
EicOsis Logo

EicOsis advancement of EC5026 into clinical trials has been funded as part of the Blueprint Neurotherapeutics Network (BPN) of the NIH Blueprint for Neuroscience Research. Read the full press release here.

Was this page helpful?
Form Approved OMB# 0925-0648 Exp. Date 05/31/2021